Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-28T15:59:16.483Z Has data issue: false hasContentIssue false

An empirical perspective on cigarette use in substance use recovery

Published online by Cambridge University Press:  15 July 2021

Renee D. Goodwin*
Affiliation:
Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
Melody Wu
Affiliation:
Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, USA Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
Larry Davidson
Affiliation:
Department of Psychiatry, School of Medicine at Yale University, New Haven, CT, USA
*
Author for correspondence: Renee D. Goodwin, E-mail:renee.goodwin@sph.cuny.edu
Rights & Permissions [Opens in a new window]

Abstract

Type
Editorial
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Introduction

Among Americans with substance use disorders (SUDs), polysubstance use is the rule rather than the exception. SUDs are identified by a pattern of problematic behaviors coalescing around a particular substance or substances (APA, 2013) without consideration of quantity or danger in single use. The majority of Americans with an SUD use at least one other substance in addition to their ‘primary’ drug (Jones & McCance-Katz, Reference Jones and McCance-Katz2019; Jones, Mogali, & Comer, Reference Jones, Mogali and Comer2012; Rowe, Santos, Behar, & Coffin, Reference Rowe, Santos, Behar and Coffin2016). Despite widespread tobacco use and co-use with other substances, and tobacco use remaining the leading cause of premature death and disease in the USA (CDC, 2014), tobacco use is rarely factored into national estimates of co-occurring substance use or SUD (Muilenburg, Laschober, Eby, & Moore, Reference Muilenburg, Laschober, Eby and Moore2016) or in clinical settings (Rowe et al., Reference Rowe, Santos, Behar and Coffin2016).

This paper explores why tobacco is not considered a ‘substance’ akin to alcohol and illicit substances in the SUD treatment setting and examines whether this differential consideration may influence SUD treatment outcomes and long-term recovery. To our knowledge, overlooking tobacco as a substance of addiction when considering polysubstance use and disorder is a historical artifact rather than an evidence-based decision. We will provide a historical context for the exclusion of tobacco from the SUD treatment paradigm and systematically examine the prevalence, associated harms, and standard SUD treatment guidelines for alcohol and tobacco co-use v. alcohol and cocaine co-use to assess the empirical basis for the disparate approach toward tobacco v. other substances. Cocaine was chosen due to the strong socio-cultural relationship that tobacco and cocaine use share with alcohol use, as well as a robust research history. The comparison of alcohol and tobacco co-use v. alcohol and cocaine co-use is not meant to provide a comprehensive review of polysubstance treatment paradigms, but to highlight the lack of evidence base for the exclusion of tobacco treatment in SUD treatment settings.

The exclusion of tobacco from SUD treatment

Over 3.7 million individuals over age 12 received substance use treatment for illicit drugs or alcohol in 2018 (SAMHSA). American SUD treatment is guided by the axiom of abstinence from all ‘drugs of addiction’. Both the National Association of Addiction Treatment Providers (NAATP) and the American Psychiatric Association (APA) uphold abstinence from addictive substances as a critical component of SUD treatment success (APA, 2006; NAATP, 2019). Alcoholics Anonymous (AA) and related 12-step groups, which are nearly ubiquitous across the SUD treatment landscape, also prioritize abstinence as an essential part of recovery, sobriety, and well-being (Gorski & Miller, Reference Gorski and Miller2013; SAMHSA, 2018).

However, the traditional treatment method of abstinence largely does not include abstinence from tobacco use. Cigarette smoking is normalized in member stories within AA's canon ‘The Big Book’ (W, Reference W1955). This acceptance of tobacco use may be related to the fact that tobacco use is legal for adults and does not cause intoxication/inebriation when used in the absence of other substance use, though arguably it does when used in combination with other substances (e.g. alcohol). It also does not generally lead to immediate life-threatening harm. Historically, smoking cessation has been considered counterproductive to SUD treatment with providers even suggesting that quitting cigarettes may increase risk of relapse to other substance use (Guydish, Passalacqua, Tajima, & Manser, Reference Guydish, Passalacqua, Tajima and Manser2007; Patten, Martin, & Owen, Reference Patten, Martin and Owen1996). Mental health treatment providers have also long espoused the belief that quitting smoking would exacerbate mental health problems among those in treatment settings, thereby inadvertently or even explicitly discouraging quitting tobacco (Sheals, Tombor, McNeill, & Shahab, Reference Sheals, Tombor, McNeill and Shahab2016). Clinicians may lack adequate training in tobacco cessation counseling as well as face competing treatment demands that, within the current treatment structure, take priority over nicotine dependence (ND) (Rogers & Sherman, Reference Rogers and Sherman2014; Rogers, Gillespie, Smelson, & Sherman, Reference Rogers, Gillespie, Smelson and Sherman2018). As such, unlike alcohol and illicit substance use and despite nicotine being a highly addictive substance, tobacco use appears currently to be exempt from inclusion in the abstinence paradigm in SUD treatment settings (National Institute on Drug Abuse, 2020).

Yet, many treatment facilities have begun restricting tobacco smoking in some manner. As of 2017, 57% of surveyed SUD treatment facilities only allowed smoking in designated areas, while 35% had complete smoke-free policies (SAMHSA, 2018). The rationale for these smoking restrictions thus far is primarily due to smoke-free workplace legislation, and not whether tobacco use should be treated because its continued use may impact abstinence, detoxification, and recovery from other substance use problems (Das & Prochaska, Reference Das and Prochaska2017; Derefinko, García, & Sumrok, Reference Derefinko, García and Sumrok2018; Muilenburg et al., Reference Muilenburg, Laschober, Eby and Moore2016; Prochaska, Delucchi, & Hall, Reference Prochaska, Delucchi and Hall2004; Tsoh, Chi, Mertens, & Weisner, Reference Tsoh, Chi, Mertens and Weisner2011).

Despite the inclusion of ND as a discrete disease, beginning with the Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) and culminating with the DSM-5 when ND was reconfigured and termed tobacco use disorder (TUD) with the diagnostic criteria now identical to other SUDs (Neuman, Bitton, & Glantz, Reference Neuman, Bitton and Glantz2005), tobacco use continues to be differentiated from other addictive substances culturally and clinically. Additionally, cigarette smoking is disproportionately common among individuals with non-tobacco SUDs relative to the general US population (Baca & Yahne, Reference Baca and Yahne2009). The past-30-day prevalence of cigarette use in 2017 in the USA was approximately 14% (Wang et al., Reference Wang, Asman, Gentzke, Cullen, Holder-Hayes, Reyes-Guzman and King2018) and past-year prevalence was 66.7% among those with a past-year diagnosis of drug abuse or dependence (Smith, Mazure, & McKee, Reference Smith, Mazure and McKee2014). Among those who seek treatment for an SUD, cigarette smoking prevalence estimates range from 65% to over 90%, which is in stark contrast to the decline in smoking among the US population (CDC, 2014; Guydish et al., Reference Guydish, Passalacqua, Tajima, Chan, Chun and Bostrom2011, Reference Guydish, Yip, Le, Gubner, Delucchi and Roman2017; Richter, Gibson, Ahluwalia, & Schmelzle, Reference Richter, Gibson, Ahluwalia and Schmelzle2001).

Tobacco use among individuals with SUDs is a public health concern that requires further surveillance and consideration (Moeller et al., Reference Moeller, Fink, Gbedemah, Hasin, Galea, Zvolensky and Goodwin2018; Weinberger et al., Reference Weinberger, Platt, Esan, Galea, Erlich and Goodwin2017b). Smoking is associated with longer, more persistent SUDs (Baca & Yahne, Reference Baca and Yahne2009; Barrett, Tichauer, Leyton, & Pihl, Reference Barrett, Tichauer, Leyton and Pihl2006; Lajtha & Sershen, Reference Lajtha and Sershen2010; Verplaetse & McKee, Reference Verplaetse and McKee2017); worse treatment outcomes (Durazzo, Pennington, Schmidt, & Meyerhoff, Reference Durazzo, Pennington, Schmidt and Meyerhoff2014; Weinberger et al., Reference Weinberger, Platt, Esan, Galea, Erlich and Goodwin2017b); a higher likelihood of using multiple substances (Attaiaa, Beck, Richard, Marimoutou, & Mayet, Reference Attaiaa, Beck, Richard, Marimoutou and Mayet2016; Lai, Lai, Page, & McCoy, Reference Lai, Lai, Page and McCoy2000; Nicksic & Barnes, Reference Nicksic and Barnes2019; Ren & Lotfipour, Reference Ren and Lotfipour2019; Silveira et al., Reference Silveira, Conway, Green, Kasza, Sargent, Borek and Compton2018); relapse to SUDs (Weinberger et al., Reference Weinberger, Platt, Esan, Galea, Erlich and Goodwin2017b; Weinberger, Platt, Jiang, & Goodwin, Reference Weinberger, Platt, Jiang and Goodwin2015); and a multiplicative effect on physical health risks when used with other substances (Baca & Yahne, Reference Baca and Yahne2009). Increasingly, data suggest that nicotine and cigarette use is also a barrier to long-term abstinence from alcohol, cannabis, and illicit substances (Peters, Budney, & Carroll, Reference Peters, Budney and Carroll2012; Prochaska et al., Reference Prochaska, Delucchi and Hall2004). Despite growing evidence of the negative effects of tobacco on the health of those with SUDs, smoking cessation interventions continue to be inconsistently delivered, optional, or not offered at all in SUD treatment settings.

A comparison of alcohol and cocaine v. alcohol and tobacco

Prevalence of alcohol and cocaine co-use

Alcohol, either as the primary or secondary substance, is the most frequently reported substance across all SUD treatment admissions at 49% (Center for Behavioral Health Statistics and Quality, 2017). Alcohol and cocaine are the two most frequently co-used substances among individuals seeking SUD treatment (Kedia, Sell, & Relyea, Reference Kedia, Sell and Relyea2007; Liu, Williamson, Setlow, Cottler, & Knackstedt, Reference Liu, Williamson, Setlow, Cottler and Knackstedt2018). Alcohol use disorder (AUD) is typically reported as the primary SUD, while cocaine use disorder (CUD) is commonly reported as a secondary SUD (Center for Behavioral Health Statistics and Quality, 2017). For individuals with primary CUD, secondary AUD is frequently reported, with an estimated 60% of individuals with CUD regardless of treatment status also meeting the criteria for AUD (Heil, Badger, & Higgins, Reference Heil, Badger and Higgins2001). Alcohol and cocaine use are treated simultaneously in nearly all SUD treatment settings.

Prevalence of alcohol and tobacco co-use

Tobacco products and alcohol are, commonly co-used; individuals who meet the criteria for both AUD and TUD represent 34.0% of all AUD cases and 22.8% of all TUD cases (Grant, Hasin, Chou, Stinson, & Dawson, Reference Grant, Hasin, Chou, Stinson and Dawson2004). The prevalence of co-occurrence among individuals seeking SUD treatment is unknown as this information is not routinely collected at intake or discharge. The link between TUD and AUD seems persistent regardless of interest in quitting cigarettes; individuals with SUD experience significantly lower quit rates and more rapid relapse than individuals without SUDs (Weinberger, Gbedemah, & Goodwin, Reference Weinberger, Gbedemah and Goodwin2017a; Weinberger et al., Reference Weinberger, Platt, Esan, Galea, Erlich and Goodwin2017b, Reference Weinberger, Pacek, Wall, Gbedemah, Lee and Goodwin2020). This is potentially due to a variety of barriers to effective cessation interventions in this population (Schroeder & Morris, Reference Schroeder and Morris2010), as well as changes to the brain reward pathway in those who co-use (Bandiera et al., Reference Bandiera, Almeida, Hansen, Pulcinelli, Caletti, de Paula and Gomez2020; Lajtha & Sershen, Reference Lajtha and Sershen2010). Overall, the lack of emphasis on tobacco treatment in the SUD treatment setting does not appear attributable to low prevalence of co-use or lack of evidence-based treatments, as these are more plentiful for TUD than any other SUD (Thurgood, McNeill, Clark-Carter, & Brose, Reference Thurgood, McNeill, Clark-Carter and Brose2016). Lack of assessment and diagnosis of TUD, especially as primary diagnosis, and insufficient third-party payer reimbursement for TUD treatment effectively prohibit comprehensive treatment of SUDs by leaving TUD untreated (Williams, Steinberg, Kenefake, & Burke, Reference Williams, Steinberg, Kenefake and Burke2016).

The physical and psychiatric harms of co-use

The harms of alcohol and cocaine

The physical, psychiatric, and social ramifications of AUD and CUD, individually and in combination, are well documented (Hedden, Malcolm, & Latimer, Reference Hedden, Malcolm and Latimer2009). AUD increases the risk of physical injury, hastens the development of chronic health conditions, and provokes and worsens mental health (CDC, 2018; WHO, 2010). CUD is implicated in unpredictable or aberrant behavior, gastrointestinal damage, cardiovascular complications, and impaired cognitive functioning (NIDA, 2016; WHO, 2010). Alcohol and cocaine co-use is also associated with increased risk of cardiovascular disease, mental health problems, and interpersonal difficulties, over and above the risk for each individually (Hedden et al., Reference Hedden, Malcolm and Latimer2009). The significant and well-documented health risks associated with alcohol and cocaine used alone or together make AUD and CUD priorities in SUD screening, assessment, and intervention.

The harms of alcohol and tobacco

As discussed earlier, AUD negatively impacts an individual's health in a myriad of ways, including harming cardiovascular, cognitive, mental, and interpersonal well-being. The physical health risks of tobacco use are well-known and extensive, including but not limited to respiratory infections, high blood pressure, diabetes, pregnancy complications, and lung cancer (WHO, 2010). In addition, cigarette use increases the number of mentally unhealthy days (Plurphanswat, Kaestner, & Rodu, Reference Plurphanswat, Kaestner and Rodu2017), and is associated with higher risk of recurrence of major depressive disorder (Bakhshaie, Zvolensky, & Goodwin, Reference Bakhshaie, Zvolensky and Goodwin2015). Co-use of alcohol and tobacco is associated with greater physical health risks relative to the use of either alone (Schroeder, Reference Schroeder2017), and is associated with mental health problems (Cohn et al., Reference Cohn, Johnson, Rose, Pearson, Villanti and Stanton2018). Among individuals in long-term recovery for AUD, cigarette smoking-related health conditions are the most common cause of death (Alcoholism: Clinical & Experimental Research, 2008). As such, the rationale for excluding tobacco use from the treatment setting does appear to be based on the lack of potential harm.

Clinical treatment processes

Considering the negative health consequences that can result from dependence on alcohol, cocaine, and tobacco, there is a clear need for screening and provision of comprehensive evidence-based tobacco treatment on par with other SUD treatments (Apollonio, Philipps, & Bero, Reference Apollonio, Philipps and Bero2016; Das & Prochaska, Reference Das and Prochaska2017; Derefinko et al., Reference Derefinko, García and Sumrok2018; Thurgood et al., Reference Thurgood, McNeill, Clark-Carter and Brose2016). Screening for AUD and CUD occurs in various contexts, including emergency departments, primary care clinics, and community mental health settings. SUD treatment referrals are generally governed by the American Society of Addiction Medicine (ASAM) Criteria – a multidimensional tool used to assess appropriate treatment services (individual counseling, inpatient, etc.) that match the intensity of need (ASAM, 2019). As of 2006, the ASAM Criteria were required by more than 30 states when making SUD treatment referrals (ASAM, 2019; Kolsky, Reference Kolsky2006). These criteria account for the specific SUD diagnosis and the individual's unique circumstances when determining the appropriate level of care (Williams et al., Reference Williams, Steinberg, Kenefake and Burke2016). Patients with more severe SUDs (i.e. those with high risk of death in the early stages of abstinence and withdrawal) and/or more challenging circumstances (e.g. those with poor health) are more often referred to inpatient treatment. Of note, TUD is not included as part of the ASAM assessment. This lack of data collection along with the lack of insurance coverage of inpatient or outpatient admissions for TUD (Williams et al., Reference Williams, Steinberg, Kenefake and Burke2016) – and therefore omission of diagnosis or downgrade to secondary diagnosis – leave a substantial gap in substance use research and treatment. Although the Agency for Healthcare Research & Quality (AHRQ) recommends that healthcare providers ‘ask’, ‘advise’, ‘assess’, ‘assist’, and ‘arrange’ for assistance for (5 A's) all patients who identify as smokers (AHRQ, 2012), only 6.1% of adult smokers reported receiving all 5 A's and 6.3% reported arrangements for follow-up regarding smoking cessation in the 2009–2010 National Adult Tobacco Survey (Kruger, O'Halloran, Rosenthal, Babb, & Fiore, Reference Kruger, O'Halloran, Rosenthal, Babb and Fiore2016). Furthermore, the ‘assist’ step only recommends brief counseling and medication (CDC). As a result, the current approach is not sufficiently potent to treat TUD. When tobacco use is assessed in clinical settings, which is not a universal practice (SAMHSA, 2018), the information is not generally collected for diagnostic purposes. Paradoxically, there is more evidence to support the effectiveness of tobacco treatments than for other SUD treatments (Thurgood et al., Reference Thurgood, McNeill, Clark-Carter and Brose2016), but comprehensive tobacco treatments such as counseling and pharmacotherapy are neither routinely accessible nor reimbursed (Williams et al., Reference Williams, Steinberg, Kenefake and Burke2016).

A paucity of treatment guidelines for co-occurring SUDs

Alcohol and cocaine co-use treatment

Co-occurring alcohol and cocaine SUDs, compared with either alone, produce additional challenges for successful treatment. These challenges include intertwined cues, modified and enhanced intoxication effects, and increased use of both substances. Individuals who become accustomed to cocaine use after consuming alcohol find themselves ‘craving’ cocaine when confronted with the conditioned cue (i.e. alcohol). When two or more substances have reciprocal cues, they are ‘intertwined’. This poses significant difficulties for those who have a combined cocaine and alcohol polysubstance disorder, as they require complete abstinence from both substances to avoid eliciting a compounding desire for one substance or the other (Marks, Pike, Stoops, & Rush, Reference Marks, Pike, Stoops and Rush2015).

Cocaine and alcohol can also modulate user experiences to amplify positive effects and mitigate negative consequences (Perez-Reyes, Reference Perez-Reyes1994). When consumed together, alcohol and cocaine create cocaethylene, a metabolite with additional psychoactive effects. Individuals who co-use cocaine and alcohol experience increased euphoria compared with the use of either substance alone (Farre et al., Reference Farre, de la Torre, Gonzalez, Teran, Roset, Menoyo and Cami1997; Liu et al., Reference Liu, Williamson, Setlow, Cottler and Knackstedt2018; McCance-Katz, Kosten, & Jatlow, Reference McCance-Katz, Kosten and Jatlow1998). Furthermore, cocaine may be used to strategically counteract alcohol's depressant effects, and alcohol may likewise be used to mitigate cocaine's withdrawal symptoms (Margolin, Avants, & Kosten, Reference Margolin, Avants and Kosten1996). Likely related to many of the reasons above, research indicates that alcohol and cocaine co-use is associated with increased frequency of use of both substances (Gossop, Manning, & Ridge, Reference Gossop, Manning and Ridge2006; Heil et al., Reference Heil, Badger and Higgins2001). Given that alcohol and cocaine cessation is required upon treatment entry, SUD interventions and programs acknowledge how alcohol and cocaine use are often inextricably entangled.

Evidence-based interventions for different SUDs usually follow similar intervention methods, such as pharmacotherapy, behavioral therapy, and addressing comorbidities, with slight substance-specific differences and differences unique to the individual. While alcohol and cocaine use are strongly associated in populations receiving treatment (Pennings, Leccese, & Wolff, Reference Pennings, Leccese and Wolff2002), there are no nationally mandated evidence-based clinical guidelines for treating co-occurring AUD and CUD. The APA recommends incorporating evidence-based practices for each SUD into an individualized plan for the patient (APA, 2006). Similarly, some local AA groups incorporate support for both alcohol and cocaine and recommend that individuals with co-occurring SUDs attend other 12-step groups (e.g. Narcotics Anonymous, Cocaine Anonymous) (W, Reference W2017). Successful CUD treatment outcomes are predicted by lower alcohol consumption after CUD treatment, while research specific to the effect of cocaine use on AUD treatment success is sparse. However, data suggest that co-morbid CUD causes an increased early treatment drop-out effect due to the difficult nature of initial cocaine abstinence, likely leading to significant difficulties in obtaining alcohol abstinence (Kampman et al., Reference Kampman, Pettinati, Volpicelli, Oslin, Lipkin, Sparkman and O'Brien2004).

Alcohol and tobacco co-use treatment

Alcohol and tobacco co-use presents challenges to treatment success not unlike that of alcohol and cocaine co-use: intertwined cues, modified and enhanced intoxication effects, and increased use of both substances. The intertwined cues for individuals with co-occurring AUD and TUD are similar for co-occurring AUD and CUD – those who use both cigarettes and alcohol find themselves wanting to use alcohol while they are smoking cigarettes, or smoke cigarettes while they are consuming alcohol.

Regardless of whether an individual uses alcohol or tobacco first, use of one substance appears to increase craving for the other (Bien & Burge, Reference Bien and Burge1990; Schroeder, Reference Schroeder2017; Sharma, Lodhi, Sahota, & Thakkar, Reference Sharma, Lodhi, Sahota and Thakkar2015). Smoking cigarettes while drinking alcohol may counteract alcohol's depressive effects, increase feelings of intoxication, and allow the individual to continue drinking (Sharma et al., Reference Sharma, Lodhi, Sahota and Thakkar2015; Verplaetse & McKee, Reference Verplaetse and McKee2017). With increased alcohol consumption, one needs to smoke more to feel the effects of tobacco (Kohut, Reference Kohut2017). Due to the reinforcing nature of alcohol and tobacco co-use, individuals using both substances may experience increased frequency of use and amount of consumption of each substance (Gulliver et al., Reference Gulliver, Rohsenow, Colby, Dey, Abrams, Niaura and Monti1995; Rohsenow et al., Reference Rohsenow, Monti, Colby, Gulliver, Sirota, Niaura and Abrams1997; Schroeder, Reference Schroeder2017; Verplaetse & McKee, Reference Verplaetse and McKee2017). The degree to which alcohol and tobacco co-use is comparably entangled with that of alcohol and cocaine co-use illustrates the need for integrated treatment that recognizes the role of each substance in perpetuating addiction and how both may be a barrier to recovery.

Akin to the lack of integrated treatment for co-occurring AUD and CUD, there are no established interventions for combined AUD and TUD treatment, though concurrent v. delayed smoking cessation is associated with lower alcohol craving and expectations of more negative effects of alcohol use (Cooney et al., Reference Cooney, Litt, Sevarino, Levy, Kranitz, Sackler and Cooney2015). Smoking cessation interventions are inconsistently provided in treatment settings and are generally optional, if available. Data on who receives TUD treatment indicate individualized, situational, and biased allocation. SUD patients experiencing physical and psychological distress receive fewer tobacco cessation services, but patients who ask for cessation services and patients who receive treatment at tobacco-free facilities are more likely to receive assistance (Guydish et al., Reference Guydish, Yip, Le, Gubner, Williams and Delucchi2019). In contrast with cocaine use in the context of AUD treatment, abstinence from tobacco is not required or emphasized.

Although the health consequences of tobacco are universally recognized, much debate remains about the role of smoking cessation interventions in SUD treatment. Addiction providers historically believed that smoking cessation during recovery would increase risk of relapse to other substance use and recommended smoking cessation after successful SUD treatment (Guydish et al., Reference Guydish, Passalacqua, Tajima and Manser2007; Patten et al., Reference Patten, Martin and Owen1996). However, available research indicates that smoking cessation interventions do not compromise SUD treatment outcomes, and instead may facilitate better outcomes when offered with SUD treatment (Baca & Yahne, Reference Baca and Yahne2009; Bobo, McIlvain, Lando, Walker, & Leed-Kelly, Reference Bobo, McIlvain, Lando, Walker and Leed-Kelly1998; Epstein, Marrone, Heishman, Schmittner, & Preston, Reference Epstein, Marrone, Heishman, Schmittner and Preston2010). In a meta-analysis of 19 randomized controlled trials, smoking interventions concurrent with SUD treatment were associated with a 25% increased chance of long-term substance abstinence (Prochaska et al., Reference Prochaska, Delucchi and Hall2004). Several studies have suggested that smoking v. no smoking is associated with poorer AUD treatment outcomes, including increased risk of relapse (Joseph, Willenbring, Nugent, & Nelson, Reference Joseph, Willenbring, Nugent and Nelson2004; Satre, Kohn, & Weisner, Reference Satre, Kohn and Weisner2007; Stuyt, Reference Stuyt2015). As such, the omission of tobacco treatment and abstinence from tobacco as a fundamental component of SUD treatment appears to contradict available evidence.

Concluding remarks

Challenges to tobacco cessation in SUD treatment settings

The physical health consequences of tobacco are devastating, with half a million US adults dying from tobacco-related causes annually (Carter et al., Reference Carter, Abnet, Feskanich, Freedman, Hartge, Lewis and Jacobs2015; CDC, 2014). Nonetheless, cigarette smoking continues to be regarded as irrelevant or of far lesser importance in SUD treatment settings. There are mixed opinions about this differential treatment among SUD treatment providers. These sentiments may be partially explained by the absence of visible tobacco ‘intoxication’ when used in the absence of other substances and the empirically unsupported belief that the effects of smoking are limited to physical consequences; numerous studies indicate that tobacco is associated with poorer mental health outcomes (e.g. Bakhshaie et al., Reference Bakhshaie, Zvolensky and Goodwin2015; Fluharty, Taylor, Grabski, & Munafò, Reference Fluharty, Taylor, Grabski and Munafò2017; Plurphanswat et al., Reference Plurphanswat, Kaestner and Rodu2017).

There are many challenges to incorporating tobacco cessation interventions into recovery-oriented settings. While inpatient facilities are quickly adopting smoke-free policies, it is feared that these policies could drive participants who smoke to leave before completing their treatment (Patten et al., Reference Patten, Martin and Owen1996). Psychoeducation of providers and patients about the benefits of TUD treatment may be necessary due to the erroneous belief that continued smoking enhances mental health and that cessation would undermine mental health recovery or successful treatment of other substance use problems (Gentry, Craig, Holland, & Notley, Reference Gentry, Craig, Holland and Notley2017; Kelly, Greene, Hoffman, Hoeppner, & Bergman, Reference Kelly, Greene, Hoffman, Hoeppner and Bergman2020; Pagano, Tajima, & Guydish, Reference Pagano, Tajima and Guydish2016; Wilson et al., Reference Wilson, Bonevski, Dunlop, Shakeshaft, Tzelepis, Walsberger and Guillaumier2016). Continued smoking alleviates withdrawal symptoms, which can mimic symptoms of anxiety, depression, and psychosis, yet evidence to the contrary suggests that cessation is associated with improved mental health and sustained SUD remission (Bakhshaie et al., Reference Bakhshaie, Zvolensky and Goodwin2015; Bakhshaie, Zvolensky, & Goodwin, Reference Bakhshaie, Zvolensky and Goodwin2016; Patkar et al., Reference Patkar, Lundy, Leone, Weinstein, Gottheil and Steinberg2002). Furthermore, smokers with and without mental disorders report similar levels of motivation to quit smoking (Siru, Hulse, & Tait, Reference Siru, Hulse and Tait2009), and so a focus on making TUD treatment integral within substance use treatment settings, in line with the approach to all other substances, may be more beneficial than assessing whether patients want to or are ready to quit tobacco use. Lack of interest in treatment for TUD would be more effectively addressed with therapeutic rationale, which better aligns with the traditional SUD treatment approach of abstinence from all substances, as well as evidence from the literature on SUD treatment outcomes.

The high prevalence of mental health problems among individuals with SUDs overall may provide additional challenges to successful treatment, but there is no evidence that it presents a disproportionately greater barrier to TUD v. CUD or AUD treatment. Furthermore, diagnosis of mental health problems should not preclude requirement for TUD treatment among substance use care settings. Additional challenges exist toward implementation of tobacco cessation services in SUD treatment facilities desiring them, including inadequate cessation resources, high prevalence of smoking among facility staff, and organizational cultures that do not prioritize cessation (Guydish et al., Reference Guydish, Passalacqua, Tajima and Manser2007; Knudsen, Reference Knudsen2017). Compounding these issues is the proliferation of non-cigarette tobacco products and widespread increase in their use, the increase in polytobacco product use, which is associated with lower odds of quitting (Guydish et al., Reference Guydish, Tajima, Pramod, Le, Gubner, Campbell and Roman2016; Wang-Schweig, Jason, Stevens, & Chaparro, Reference Wang-Schweig, Jason, Stevens and Chaparro2019), and the increase in use of products that are often used to co-administer tobacco and cannabis (Baldassarri et al., Reference Baldassarri, Fiellin, Savage, Madden, Beitel, Dhingra and Barry2019; Dixit, Herbst, & Das, Reference Dixit, Herbst and Das2021; Guydish et al., Reference Guydish, Tajima, Pramod, Le, Gubner, Campbell and Roman2016; Wang-Schweig et al., Reference Wang-Schweig, Jason, Stevens and Chaparro2019). E-cigarettes, for example, are often permitted in SUD treatment facilities where combustible tobacco use is prohibited (Wang-Schweig et al., Reference Wang-Schweig, Jason, Stevens and Chaparro2019).

Public health implications

The current paper presents an empirical perspective on the debate over whether to treat TUD in SUD treatment settings. The weight of the available evidence suggests that continued smoking is associated with poorer SUD treatment outcomes and increased risk of relapse during SUD recovery. Available data on treatment outcomes for cocaine and alcohol co-use mirror those of tobacco and alcohol co-use, suggesting a major discrepancy in the perception v. the reality of the impact of tobacco and alcohol co-use on SUD recovery.

Additionally, no evidence to date suggests that tobacco use is an effective tool in remaining abstinent from other substance use. Yet, it is possible that offering tobacco treatment services as a follow-up to AUD treatment may be more effective for individuals who do not request simultaneous treatment (Kodl, Fu, & Joseph, Reference Kodl, Fu and Joseph2006). This question has not been explored empirically but warrants thorough investigation given the widespread practice and profound risks of tobacco use. Regardless of provider preferences, philosophies, or the historical background of SUD treatment resources, the data suggest that continued smoking may be undermining SUD treatment efforts. As we continue to develop evidence-based SUD treatment guidelines, it seems illogical to continue with the status quo of sustained or encouraged tobacco use. A change this profound requires resources, time, and attention, as well as input from all key stakeholders, to address and change longstanding culture. As we amass more data, re-classification of cigarette use within the SUD treatment model as part of the problem, rather than inconsequential, has the potential to make a profound impact toward moving the field forward.

Financial support

This work was supported by the National Institutes of Health/National Institute on Drug Abuse (RDG, grant number R01-DA20892).

Conflict of interest

None.

References

AHRQ. (2012). Five major steps to intervention (the ‘5 A's’). Treating tobacco use and dependence. Retrieved from https://www.ahrq.gov/prevention/guidelines/tobacco/5steps.html.Google Scholar
Alcoholism: Clinical & Experimental Research. (2008). Coffee and cigarette consumption are high among AA attendees [Press release]. Retrieved from https://www.eurekalert.org/pub_releases/2008-07/ace-cac071308.php.Google Scholar
APA. (2006). Practice guideline for the treatment of patients with substance use disorders. Retrieved from https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf.Google Scholar
APA. (2013). Diagnostic and statistical manual of mental disorders (DSM-5): American Psychiatric Association.Google Scholar
Apollonio, D., Philipps, R., & Bero, L. (2016). Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database of Systematic Reviews (11).CrossRefGoogle ScholarPubMed
ASAM. (2019). What is the ASAM Criteria? Retrieved from https://www.asam.org/resources/the-asam-criteria/about.Google Scholar
Attaiaa, L.-A., Beck, F., Richard, J.-B., Marimoutou, C., & Mayet, A. (2016). Relationships between substance initiation sequence and further substance use: A French nationwide retrospective study. Addictive Behaviors, 57, 15. doi: doi:10.1016/j.addbeh.2016.01.009.CrossRefGoogle ScholarPubMed
Baca, C. T., & Yahne, C. E. (2009). Smoking cessation during substance abuse treatment: What you need to know. Journal of Substance Abuse Treatment, 36(2), 205219. doi: doi:10.1016/j.jsat.2008.06.003.CrossRefGoogle ScholarPubMed
Bakhshaie, J., Zvolensky, M. J., & Goodwin, R. D. (2015). Cigarette smoking and the onset and persistence of depression among adults in the United States: 1994–2005. Comprehensive Psychiatry, 60, 142148. doi: doi:10.1016/j.comppsych.2014.10.012.CrossRefGoogle ScholarPubMed
Bakhshaie, J., Zvolensky, M. J., & Goodwin, R. D. (2016). Cigarette smoking and the onset and persistence of panic attacks during mid-adulthood in the United States: 1994–2005. Journal of Clinical Psychiatry, 77(1), e21e24. doi: doi:10.4088/JCP.14m09290.CrossRefGoogle ScholarPubMed
Baldassarri, S. R., Fiellin, D. A., Savage, M. E., Madden, L. M., Beitel, M., Dhingra, L. K., … Barry, D. T. (2019). Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment. Drug and Alcohol Dependence, 197, 3741.CrossRefGoogle ScholarPubMed
Bandiera, S., Almeida, F. B., Hansen, A. W., Pulcinelli, R. R., Caletti, G., de Paula, L. F., … Gomez, R. (2020). Combined use of alcohol and cigarette increases locomotion and glutamate levels in the cerebrospinal fluid without changes on GABA(A) or NMDA receptor subunit mRNA expression in the hippocampus of rats. Behavioural Brain Research, 380, 112444. doi: doi:10.1016/j.bbr.2019.112444.CrossRefGoogle ScholarPubMed
Barrett, S. P., Tichauer, M., Leyton, M., & Pihl, R. O. (2006). Nicotine increases alcohol self-administration in non-dependent male smokers. Drug and Alcohol Dependence, 81(2), 197204.CrossRefGoogle ScholarPubMed
Bien, T. H., & Burge, R. (1990). Smoking and drinking: A review of the literature. International Journal of the Addictions, 25(12), 14291454.CrossRefGoogle ScholarPubMed
Bobo, J. K., McIlvain, H. E., Lando, H. A., Walker, R. D., & Leed-Kelly, A. (1998). Effect of smoking cessation counseling on recovery from alcoholism: Findings from a randomized community intervention trial. Addiction, 93(6), 877887.CrossRefGoogle ScholarPubMed
Carter, B., Abnet, C., Feskanich, D., Freedman, N., Hartge, P., Lewis, C., … Jacobs, E. (2015). Smoking and mortality: Beyond established causes. New England Journal of Medicine, 372(7), 631640.CrossRefGoogle ScholarPubMed
CDC (2014). The health consequences of smoking – 50 years of progress: A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.Google Scholar
CDC. (2018). Alcohol use and your health. Retrieved from https://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm.Google Scholar
Center for Behavioral Health Statistics and Quality. (2017). Treatment Episode Data Set (TEDS): 2005–2015. National admissions to substance abuse treatment services. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/sites/default/files/2015_Treatment_Episode_Data_Set_National/2015_Treatment_Episode_Data_Set_National.pdf.Google Scholar
Cohn, A. M., Johnson, A. L., Rose, S. W., Pearson, J. L., Villanti, A. C., & Stanton, C. (2018). Population-level patterns and mental health and substance use correlates of alcohol, marijuana, and tobacco use and co-use in US young adults and adults: Results from the population assessment for tobacco and health. American Journal on Addictions, 27(6), 491500. doi: doi:10.1111/ajad.12766.CrossRefGoogle Scholar
Cooney, N. L., Litt, M. D., Sevarino, K. A., Levy, L., Kranitz, L. S., Sackler, H., & Cooney, J. L. (2015). Concurrent alcohol and tobacco treatment: Effect on daily process measures of alcohol relapse risk. Journal of Consulting and Clinical Psychology, 83(2), 346.CrossRefGoogle ScholarPubMed
Das, S., & Prochaska, J. J. (2017). Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders. Expert Review of Respiratory Medicine, 11(10), 841850.CrossRefGoogle ScholarPubMed
Derefinko, K. J., García, F. I. S., & Sumrok, D. D. (2018). Smoking cessation for those pursuing recovery from substance use disorders. Medical Clinics, 102(4), 781796.Google ScholarPubMed
Dixit, D., Herbst, E., & Das, S. (2021). E-cigarette use and perceptions among veterans receiving outpatient treatment in veterans affairs substance use and mental health clinics. Military Medicine, 186(1–2), 2429.CrossRefGoogle Scholar
Durazzo, T. C., Pennington, D. L., Schmidt, T. P., & Meyerhoff, D. J. (2014). Effects of cigarette smoking history on neurocognitive recovery over 8 months of abstinence in alcohol-dependent individuals. Alcoholism, Clinical and Experimental Research, 38(11), 28162825. doi: doi:10.1111/acer.12552.CrossRefGoogle ScholarPubMed
Epstein, D. H., Marrone, G. F., Heishman, S. J., Schmittner, J., & Preston, K. L. (2010). Tobacco, cocaine, and heroin: Craving and use during daily life. Addictive Behaviors, 35(4), 318324. doi: doi:10.1016/j.addbeh.2009.11.003.CrossRefGoogle ScholarPubMed
Farre, M., de la Torre, R., Gonzalez, M. L., Teran, M. T., Roset, P. N., Menoyo, E., & Cami, J. (1997). Cocaine and alcohol interactions in humans: Neuroendocrine effects and cocaethylene metabolism. Journal of Pharmacology and Experimental Therapeutics, 283(1), 164176.Google ScholarPubMed
Fluharty, M., Taylor, A. E., Grabski, M., & Munafò, M. R. (2017). The association of cigarette smoking with depression and anxiety: A systematic review. Nicotine & Tobacco Research, 19(1), 313. doi: doi:10.1093/ntr/ntw140.CrossRefGoogle ScholarPubMed
Gentry, S., Craig, J., Holland, R., & Notley, C. (2017). Smoking cessation for substance misusers: A systematic review of qualitative studies on participant and provider beliefs and perceptions. Drug and Alcohol Dependence, 180, 178192.CrossRefGoogle ScholarPubMed
Gorski, T. T., & Miller, M. (2013). Staying sober: A guide for relapse prevention (Revised ed.). Independence, Missouri: Herald House/Independence Press.Google Scholar
Gossop, M., Manning, V., & Ridge, G. (2006). Concurrent use and order of use of cocaine and alcohol: Behavioural differences between users of crack cocaine and cocaine powder. Addiction, 101(9), 12921298. doi: doi:10.1111/j.1360-0443.2006.01497.x.CrossRefGoogle ScholarPubMed
Grant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004). Nicotine dependence and psychiatric disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 61(11), 11071115. doi: doi:10.1001/archpsyc.61.11.1107.CrossRefGoogle ScholarPubMed
Gulliver, S. B., Rohsenow, D. J., Colby, S. M., Dey, A. N., Abrams, D. B., Niaura, R. S., & Monti, P. M. (1995). Interrelationship of smoking and alcohol dependence, use and urges to use. Journal of Studies on Alcohol, 56(2), 202206.CrossRefGoogle ScholarPubMed
Guydish, J., Passalacqua, E., Tajima, B., Chan, M., Chun, J., & Bostrom, A. (2011). Smoking prevalence in addiction treatment: A review. Nicotine & Tobacco Research, 13(6), 401411. doi: doi:10.1093/ntr/ntr048.CrossRefGoogle ScholarPubMed
Guydish, J., Passalacqua, E., Tajima, B., & Manser, S. T. (2007). Staff smoking and other barriers to nicotine dependence intervention in addiction treatment settings: A review. Journal of Psychoactive Drugs, 39(4), 423433. doi: doi:10.1080/02791072.2007.10399881.CrossRefGoogle ScholarPubMed
Guydish, J., Tajima, B., Pramod, S., Le, T., Gubner, N. R., Campbell, B., & Roman, P. (2016). Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment. Drug and Alcohol Dependence, 166, 9399.CrossRefGoogle Scholar
Guydish, J., Yip, D., Le, T., Gubner, N. R., Delucchi, K., & Roman, P. (2017). Smoking-related outcomes and associations with tobacco-free policy in addiction treatment, 2015–2016. Drug and Alcohol Dependence, 179, 355361. doi: doi:10.1016/j.drugalcdep.2017.06.041CrossRefGoogle Scholar
Guydish, J., Yip, D., Le, T., Gubner, N. R., Williams, D. D., & Delucchi, K. L. (2019). Tobacco cessation services in addiction treatment: What do clients say? Psychiatric Services, 70(3), 229232. doi: doi:10.1176/appi.ps.201700565.CrossRefGoogle ScholarPubMed
Hedden, S. L., Malcolm, R. J., & Latimer, W. W. (2009). Differences between adult non-drug users versus alcohol, cocaine and concurrent alcohol and cocaine problem users. Addictive Behaviors, 34(3), 323326. doi: doi:10.1016/j.addbeh.2008.11.001.CrossRefGoogle ScholarPubMed
Heil, S. H., Badger, G. J., & Higgins, S. T. (2001). Alcohol dependence among cocaine-dependent outpatients: Demographics, drug use, treatment outcome and other characteristics. Journal of Studies on Alcohol, 62(1), 1422.CrossRefGoogle ScholarPubMed
Jones, C. M., & McCance-Katz, E. F. (2019). Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug and Alcohol Dependence, 197, 7882.CrossRefGoogle ScholarPubMed
Jones, J. D., Mogali, S., & Comer, S. D. (2012). Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug and Alcohol Dependence, 125(1–2), 818. doi: doi:10.1016/j.drugalcdep.2012.07.004.CrossRefGoogle ScholarPubMed
Joseph, A. M., Willenbring, M. L., Nugent, S. M., & Nelson, D. B. (2004). A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. Journal of Studies on Alcohol, 65(6), 681691.CrossRefGoogle ScholarPubMed
Kampman, K. M., Pettinati, H. M., Volpicelli, J. R., Oslin, D. M., Lipkin, C., Sparkman, T., & O'Brien, C. P. (2004). Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. The American Journal on Addictions, 13(1), 7482. doi: doi:10.1080/10550490490265389.CrossRefGoogle ScholarPubMed
Kedia, S., Sell, M. A., & Relyea, G. (2007). Mono- versus polydrug abuse patterns among publicly funded clients. Substance Abuse Treatment, Prevention, and Policy, 2, 33. doi: doi:10.1186/1747-597X-2-33.CrossRefGoogle ScholarPubMed
Kelly, J. F., Greene, M. C., Hoffman, L. A., Hoeppner, B. B., & Bergman, B. G. (2020). On providing smoking cessation services in alcohol and other drug treatment settings: Results from a US national survey of attitudes among recovering persons. Journal of Substance Abuse Treatment, 117, 108057.CrossRefGoogle Scholar
Knudsen, H. K. (2017). Implementation of smoking cessation treatment in substance use disorder treatment settings: A review. American Journal of Drug and Alcohol Abuse, 43(2), 215225. doi: doi:10.1080/00952990.2016.1183019.CrossRefGoogle ScholarPubMed
Kodl, M., Fu, S. S., & Joseph, A. M. (2006). Tobacco cessation treatment for alcohol-dependent smokers: When is the best time? Alcohol Research & Health, 29(3), 203207.Google ScholarPubMed
Kohut, S. J. (2017). Interactions between nicotine and drugs of abuse: A review of preclinical findings. American Journal of Drug and Alcohol Abuse, 43(2), 155170. doi: doi:10.1080/00952990.2016.1209513.CrossRefGoogle ScholarPubMed
Kolsky, G. D. (2006). Current State AOD agency practices regarding the use of Patient Placement Criteria (PPC) – an update. Retrieved from https://www.asam.org/docs/publications/survey_of_state_use_of_ppc_nasadad-2006.pdf?Status=Master&sfvrsn=2.Google Scholar
Kruger, J., O'Halloran, A., Rosenthal, A. C., Babb, S. D., & Fiore, M. C. (2016). Receipt of evidence-based brief cessation interventions by health professionals and use of cessation assisted treatments among current adult cigarette-only smokers: National Adult Tobacco Survey, 2009–2010. BMC Public Health, 16(1), 110.CrossRefGoogle ScholarPubMed
Lai, S., Lai, H., Page, J. B., & McCoy, C. B. (2000). The association between cigarette smoking and drug abuse in the United States. Journal of Addictive Diseases, 19(4), 1124. doi: doi:10.1300/J069v19n04_02.CrossRefGoogle ScholarPubMed
Lajtha, A., & Sershen, H. (2010). Nicotine: Alcohol reward interactions. Neurochemical Research, 35(8), 12481258. doi: doi:10.1007/s11064-010-0181-8.CrossRefGoogle ScholarPubMed
Liu, Y., Williamson, V., Setlow, B., Cottler, L. B., & Knackstedt, L. A. (2018). The importance of considering polysubstance use: Lessons from cocaine research. Drug and Alcohol Dependence, 192, 1628. doi: doi:10.1016/j.drugalcdep.2018.07.025.CrossRefGoogle ScholarPubMed
Margolin, A., Avants, S. K., & Kosten, T. R. (1996). Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients. American Journal of Drug and Alcohol Abuse, 22(3), 377388. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8841686.CrossRefGoogle ScholarPubMed
Marks, K. R., Pike, E., Stoops, W. W., & Rush, C. R. (2015). Alcohol administration increases cocaine craving but not cocaine cue attentional bias. Alcoholism, Clinical and Experimental Research, 39(9), 18231831. doi: doi:10.1111/acer.12824.CrossRefGoogle Scholar
McCance-Katz, E. F., Kosten, T. R., & Jatlow, P. (1998). Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone: A multiple-dose study. Biological Psychiatry, 44(4), 250259. doi: doi:10.1016/S0006-3223(97)00426-5.CrossRefGoogle ScholarPubMed
Moeller, S. J., Fink, D. S., Gbedemah, M., Hasin, D. S., Galea, S., Zvolensky, M. J., … Goodwin, R. D. (2018). Trends in illicit drug use among smokers and nonsmokers in the United States, 2002–2014. Journal of Clinical Psychiatry, 79(3), e1e9. 10.4088/JCP.17m11718.Google ScholarPubMed
Muilenburg, J. L., Laschober, T. C., Eby, L. T., & Moore, N. D. (2016). Prevalence of and factors related to tobacco ban implementation in substance use disorder treatment programs. Administration and Policy in Mental Health, 43(2), 241249. doi: doi:10.1007/s10488-015-0636-y.CrossRefGoogle ScholarPubMed
NAATP. (2019). The addiction treatment provider quality assurance guidebook: a guide to the core competencies for the delivery of addiction treatment services. Retrieved from Denver, Colorado: https://www.naatp.org/sites/naatp.org/files/NAATP%20QA%20Guidebook%20Beta.pdf.Google Scholar
National Institute on Drug Abuse. (2020). Is nicotine addictive? Tobacco, Nicotine, and E-Cigarettes Research Report. Retrieved from https://www.drugabuse.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/nicotine-addictive.Google Scholar
Neuman, M. D., Bitton, A., & Glantz, S. A. (2005). Tobacco industry influence on the definition of tobacco related disorders by the American Psychiatric Association. Tobacco Control, 14(5), 328337. doi: doi:10.1136/tc.2004.010512.CrossRefGoogle ScholarPubMed
Nicksic, N. E., & Barnes, A. J. (2019). Is susceptibility to e-cigarettes among youth associated with tobacco and other substance use behaviors one year later? Results from the PATH study. Preventive Medicine, 121, 109114. doi: doi:10.1016/j.ypmed.2019.02.006.CrossRefGoogle ScholarPubMed
Pagano, A., Tajima, B., & Guydish, J. (2016). Barriers and facilitators to tobacco cessation in a nationwide sample of addiction treatment programs. Journal of Substance Abuse Treatment, 67, 2229.CrossRefGoogle Scholar
Patkar, A. A., Lundy, A., Leone, F. T., Weinstein, S. P., Gottheil, E., & Steinberg, M. (2002). Tobacco and alcohol use and medical symptoms among cocaine dependent patients. Substance Abuse, 23(2), 105114. doi: doi:10.1080/08897070209511480.CrossRefGoogle ScholarPubMed
Patten, C. A., Martin, J. E., & Owen, N. (1996). Can psychiatric and chemical dependency treatment units be smoke free? Journal of Substance Abuse Treatment, 13(2), 107118.CrossRefGoogle ScholarPubMed
Pennings, E. J., Leccese, A. P., & Wolff, F. A. (2002). Effects of concurrent use of alcohol and cocaine. Addiction, 97(7), 773783.CrossRefGoogle ScholarPubMed
Perez-Reyes, M. (1994). The order of drug administration: Its effects on the interaction between cocaine and ethanol. Life Sciences, 55(7), 541550. doi: doi:10.1016/0024-3205(94)00747-0.CrossRefGoogle ScholarPubMed
Peters, E. N., Budney, A. J., & Carroll, K. M. (2012). Clinical correlates of co-occurring cannabis and tobacco use: A systematic review. Addiction, 107(8), 14041417. doi: doi:10.1111/j.1360-0443.2012.03843.x.CrossRefGoogle ScholarPubMed
Plurphanswat, N., Kaestner, R., & Rodu, B. (2017). The effect of smoking on mental health. American Journal of Health Behavior, 41(4), 471483. doi: doi:10.5993/AJHB.41.4.12.CrossRefGoogle ScholarPubMed
Prochaska, J. J., Delucchi, K., & Hall, S. M. (2004). A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical Psychology, 72(6), 11441156. doi: doi:10.1037/0022-006X.72.6.1144.CrossRefGoogle ScholarPubMed
Ren, M., & Lotfipour, S. (2019). Nicotine gateway effects on adolescent substance use. The Western Journal of Emergency Medicine, 20(5), 696709. doi: doi:10.5811/westjem.2019.7.41661.CrossRefGoogle ScholarPubMed
Richter, K. P., Gibson, C. A., Ahluwalia, J. S., & Schmelzle, K. H. (2001). Tobacco use and quit attempts among methadone maintenance clients. American Journal of Public Health, 91(2), 296299.Google ScholarPubMed
Rogers, E. S., Gillespie, C., Smelson, D., & Sherman, S. E. (2018). A qualitative evaluation of mental health clinic staff perceptions of barriers and facilitators to treating tobacco use. Nicotine and Tobacco Research, 20(10), 12231230.CrossRefGoogle ScholarPubMed
Rogers, E., & Sherman, S. (2014). Tobacco use screening and treatment by outpatient psychiatrists before and after release of the American Psychiatric Association treatment guidelines for nicotine dependence. American Journal of Public Health, 104(1), 9095.CrossRefGoogle ScholarPubMed
Rohsenow, D. J., Monti, P. M., Colby, S. M., Gulliver, S. B., Sirota, A. D., Niaura, R. S., & Abrams, D. B. (1997). Effects of alcohol cues on smoking urges and topography among alcoholic men. Alcoholism, Clinical and Experimental Research, 21(1), 101107.CrossRefGoogle ScholarPubMed
Rowe, C., Santos, G. M., Behar, E., & Coffin, P. O. (2016). Correlates of overdose risk perception among illicit opioid users. Drug and Alcohol Dependence, 159, 234239. doi: doi:10.1016/j.drugalcdep.2015.12.018.CrossRefGoogle ScholarPubMed
SAMHSA. Table 5.9A – received substance use treatment in past year among persons aged 12 or older, by detailed age category: Numbers in thousands, 2017 and 2018. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Retrieved from https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2018R2/NSDUHDetTabsSect5pe2018.htm.Google Scholar
SAMHSA (2018). National Survey of Substance Abuse Treatment Services (N-SSATS): 2017. Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration.Google Scholar
Satre, D. D., Kohn, C. S., & Weisner, C. (2007). Cigarette smoking and long-term alcohol and drug treatment outcomes: A telephone follow-up at five years. American Journal on Addictions, 16(1), 3237. doi: doi:10.1080/10550490601077825.CrossRefGoogle ScholarPubMed
Schroeder, S. (2017). Alcohol and tobacco – can AA groups help to break the connection? Retrieved from https://smokingcessationleadership.ucsf.edu/directors-corner/alcohol-and-tobacco-can-aa-groups-help-break-connection.Google Scholar
Schroeder, S., & Morris, C. (2010). Confronting a neglected epidemic: Tobacco cessation for persons with mental illnesses and substance abuse problems. Annual Review of Public Health, 31, 297314. doi: doi:10.1146/annurev.publhealth.012809.103701.CrossRefGoogle ScholarPubMed
Sharma, R., Lodhi, S., Sahota, P., & Thakkar, M. M. (2015). Nicotine administration in the wake-promoting basal forebrain attenuates sleep-promoting effects of alcohol. Journal of Neurochemistry, 135(2), 323331. doi: doi:10.1111/jnc.13219.CrossRefGoogle ScholarPubMed
Sheals, K., Tombor, I., McNeill, A., & Shahab, L. (2016). A mixed-method systematic review and meta-analysis of mental health professionals’ attitudes toward smoking and smoking cessation among people with mental illnesses. Addiction, 111(9), 15361553.CrossRefGoogle ScholarPubMed
Silveira, M. L., Conway, K. P., Green, V. R., Kasza, K. A., Sargent, J. D., Borek, N., … Compton, W. M. (2018). Longitudinal associations between youth tobacco and substance use in waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. Drug and Alcohol Dependence, 191, 2536. doi: doi:10.1016/j.drugalcdep.2018.06.018.CrossRefGoogle ScholarPubMed
Siru, R., Hulse, G. K., & Tait, R. J. (2009). Assessing motivation to quit smoking in people with mental illness: A review. Addiction, 104(5), 719733.CrossRefGoogle ScholarPubMed
Smith, P. H., Mazure, C. M., & McKee, S. A. (2014). Smoking and mental illness in the U.S. population. Tobacco Control, 23(e2), e147e153. doi: doi:10.1136/tobaccocontrol-2013-051466.CrossRefGoogle ScholarPubMed
Stuyt, E. B. (2015). Enforced abstinence from tobacco during in-patient dual-diagnosis treatment improves substance abuse treatment outcomes in smokers. American Journal on Addictions, 24(3), 252257. doi: doi:10.1111/ajad.12179.CrossRefGoogle ScholarPubMed
Thurgood, S. L., McNeill, A., Clark-Carter, D., & Brose, L. S. (2016). A systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery. Nicotine & Tobacco Research, 18(5), 9931001.CrossRefGoogle ScholarPubMed
Tsoh, J. Y., Chi, F. W., Mertens, J. R., & Weisner, C. M. (2011). Stopping smoking during first year of substance use treatment predicted 9-year alcohol and drug treatment outcomes. Drug and Alcohol Dependence, 114(2–3), 110118.Google ScholarPubMed
Verplaetse, T. L., & McKee, S. A. (2017). An overview of alcohol and tobacco/nicotine interactions in the human laboratory. American Journal of Drug and Alcohol Abuse, 43(2), 186196. doi: doi:10.1080/00952990.2016.1189927.CrossRefGoogle ScholarPubMed
W, B. (1955). Alcoholics Anonymous: The story of how many thousands of men and women have recovered from alcoholism. New York, NY: Alcoholics Anonymous.Google Scholar
W, B. (2017). Problems other than alcohol. Retrieved from https://www.aa.org/assets/en_US/P-35_Problems_Other_than_Alcohol.pdf.Google Scholar
Wang-Schweig, M., Jason, L. A., Stevens, E., & Chaparro, J. (2019). Tobacco use among recovery home residents: Vapers less confident to quit. American Journal of Health Behavior, 43(6), 10641074.CrossRefGoogle Scholar
Wang, T., Asman, K., Gentzke, A., Cullen, K., Holder-Hayes, E., Reyes-Guzman, C., … King, B. A. (2018). Tobacco product use among adults – United States, 2017. MMWR Morbidity and Mortality Weekly Report, 67, 12251232. doi: http://dx.doi.org/10.15585/mmwr.mm6744a2External.CrossRefGoogle ScholarPubMed
Weinberger, A. H., Gbedemah, M., & Goodwin, R. D. (2017a). Cigarette smoking quit rates among adults with and without alcohol use disorders and heavy alcohol use, 2002–2015: A representative sample of the United States population. Drug and Alcohol Dependence, 180, 204207. doi: doi:10.1016/j.drugalcdep.2017.07.009CrossRefGoogle Scholar
Weinberger, A. H., Pacek, L. R., Wall, M. M., Gbedemah, M., Lee, J., & Goodwin, R. D. (2020). Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002–2016. Tobacco Control, 29(1), 7480. doi: doi:10.1136/tobaccocontrol-2018-054590CrossRefGoogle ScholarPubMed
Weinberger, A. H., Platt, J., Esan, H., Galea, S., Erlich, D., & Goodwin, R. D. (2017b). Cigarette smoking is associated with increased risk of substance use disorder relapse: A nationally representative, prospective longitudinal investigation. Journal of Clinical Psychiatry, 78(2), e152e160. doi: doi:10.4088/JCP.15m10062CrossRefGoogle Scholar
Weinberger, A. H., Platt, J., Jiang, B., & Goodwin, R. D. (2015). Cigarette smoking and risk of alcohol use relapse among adults in recovery from alcohol use disorders. Alcoholism, Clinical and Experimental Research, 39(10), 19891996. doi: doi:10.1111/acer.12840.CrossRefGoogle ScholarPubMed
WHO. (2010). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care. Retrieved from https://www.who.int/substance_abuse/publications/assist/en/.Google Scholar
Williams, J. M., Steinberg, M. L., Kenefake, A. N., & Burke, M. V. (2016). An argument for change in tobacco treatment options guided by the ASAM Criteria for patient placement. Journal of Addiction Medicine, 10(5), 291299. doi: doi:10.1097/ADM.0000000000000239.CrossRefGoogle ScholarPubMed
Wilson, A. J., Bonevski, B., Dunlop, A., Shakeshaft, A., Tzelepis, F., Walsberger, S., … Guillaumier, A. (2016). ‘The lesser of two evils’: A qualitative study of staff and client experiences and beliefs about addressing tobacco in addiction treatment settings. Drug and Alcohol Review, 35(1), 92101.CrossRefGoogle ScholarPubMed